Roger G. Owen
About
Roger G. Owen is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Roger G. Owen has authored 229 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Hematology, 101 papers in Oncology and 90 papers in Molecular Biology. Recurrent topics in Roger G. Owen's work include Multiple Myeloma Research and Treatments (127 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Protein Degradation and Inhibitors (59 papers). Roger G. Owen is often cited by papers focused on Multiple Myeloma Research and Treatments (127 papers), Chronic Lymphocytic Leukemia Research (67 papers) and Protein Degradation and Inhibitors (59 papers). Roger G. Owen collaborates with scholars based in United Kingdom, United States and Italy. Roger G. Owen's co-authors include Gareth J. Morgan, Faith E. Davies, Mark T. Drayson, J. A. Child, Sue Bell, Andrew Jack, Andy C. Rawstron, Walter M. Gregory, Peter J. Selby and Julia Brown and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Roger G. Owen
214 papers receiving 8.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Roger G. Owen United Kingdom | 41 | 5.3k | 3.7k | 3.6k | 3.0k | 2.8k | 229 | 9.1k | ||
| Edie Weller United States | 40 | 2.5k 0.5× | 3.2k 0.9× | 2.3k 0.6× | 1.7k 0.6× | 2.9k 1.0× | 131 | 7.5k | ||
| Dan Jones United States | 51 | 4.6k 0.9× | 1.9k 0.5× | 1.7k 0.5× | 4.0k 1.3× | 2.3k 0.8× | 256 | 8.6k | ||
| Curtis A. Hanson United States | 63 | 8.7k 1.7× | 1.4k 0.4× | 5.3k 1.5× | 10.9k 3.6× | 3.1k 1.1× | 393 | 14.7k | ||
| Bernhard Wörmann Germany | 40 | 3.3k 0.6× | 1.9k 0.5× | 1.9k 0.5× | 1.5k 0.5× | 1.6k 0.6× | 173 | 6.3k | ||
| Anjali S. Advani United States | 41 | 3.5k 0.7× | 2.9k 0.8× | 1.6k 0.4× | 1.2k 0.4× | 1.2k 0.4× | 298 | 7.1k | ||
| Anthony S. Stein United States | 43 | 3.9k 0.7× | 2.9k 0.8× | 1.5k 0.4× | 934 0.3× | 873 0.3× | 242 | 6.8k | ||
| Nicola Gökbuget Germany | 49 | 4.7k 0.9× | 3.8k 1.0× | 1.3k 0.4× | 1.1k 0.3× | 1.8k 0.6× | 179 | 9.1k | ||
| François Guilhot France | 62 | 14.7k 2.8× | 3.4k 0.9× | 3.0k 0.8× | 10.6k 3.5× | 1.8k 0.6× | 351 | 18.5k | ||
| Morton Coleman United States | 47 | 2.1k 0.4× | 3.0k 0.8× | 1.6k 0.4× | 3.3k 1.1× | 4.8k 1.7× | 306 | 8.2k | ||
| Sigurður Y. Kristinsson Sweden | 46 | 3.9k 0.7× | 1.6k 0.4× | 2.2k 0.6× | 2.6k 0.8× | 834 0.3× | 142 | 6.0k |
Countries citing papers authored by Roger G. Owen
Since
Specialization
Citations
This map shows the geographic impact of Roger G. Owen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger G. Owen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger G. Owen more than expected).
Fields of papers citing papers by Roger G. Owen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Roger G. Owen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger G. Owen. The network helps show where Roger G. Owen may publish in the future.
Co-authorship network of co-authors of Roger G. Owen
This figure shows the co-authorship network connecting the top 25 collaborators of Roger G. Owen. A scholar is included among the top collaborators of Roger G. Owen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger G. Owen. Roger G. Owen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stephenson, Sophie, Matthew A. Care, Roger G. Owen, et al.. (2025). Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation. Life Science Alliance. 8(10). e202402814–e202402814.
2.
Cairns, David A., Charlotte Pawlyn, Eugene B. Ferris, et al.. (2025). Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 146(22). 2670–2680.
3.
Durot, Éric, Jithma P. Abeykoon, Damien Roos‐Weil, et al.. (2025). Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia. Seminars in Hematology. 62(2). 120–125.
4.
Heyman, Benjamin, Stephen Opat, Björn E. Wahlin, et al.. (2024). Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. Blood Advances. 9(4). 722–728.
5.
Kaiser, Martin, Andrew Hall, Amy Holroyd, et al.. (2024). Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial. Blood. 144(Supplement 1). 3354–3354.
6.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281.
7.
García‐Sánz, Ramón, Zachary R. Hunter, Stéphanie Poulain, Marzia Varettoni, & Roger G. Owen. (2023). New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia. Expert Review of Hematology. 16(11). 835–847.
8.
Faustini, Sian, Andrew Hall, Sarah Brown, et al.. (2023). Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. British Journal of Haematology. 201(5). 845–850.
9.
Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955.
10.
Cairns, David A., Amy Holroyd, Charlotte Pawlyn, et al.. (2022). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 141(14). 1666–1674.
11.
Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900.
12.
Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’ , a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279.
13.
Pawlyn, Charlotte, Martin Kaiser, David A. Cairns, et al.. (2017). Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial. Blood. 130. 3040–3040.
14.
Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767.
15.
Dimopoulos, Meletios Α., Efstathios Kastritis, Roger G. Owen, et al.. (2014). Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.. UCL Discovery (University College London).
16.
Barrans, Sharon, Simon Crouch, Alex Smith, et al.. (2010). Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab. Journal of Clinical Oncology. 28(20). 3360–3365.
17.
Feyler, Sylvia, M von Lilienfeld-Toal, Sarah Jarmin, et al.. (2009). CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology. 144(5). 686–695.
18.
Gotoda, Takuji, M F Dixon, Tadakazu Shimoda, et al.. (2006). Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 55(11). 1545–1552.
19.
Ackroyd, Sam, Sheila J.M. O’Connor, & Roger G. Owen. (2005). Rarity of IgH translocations in Waldenström macroglobulinemia. Cancer Genetics and Cytogenetics. 163(1). 77–80.
20.
Owen, Roger G.. (2003). Developing diagnostic criteria in Waldenstrom's macroglobulinemia. Seminars in Oncology. 30(2). 196–200.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Edie Weller Breakdown of academic impact, for papers by Dan Jones Breakdown of academic impact, for papers by Curtis A. Hanson Breakdown of academic impact, for papers by Bernhard Wörmann Breakdown of academic impact, for papers by Anjali S. Advani Breakdown of academic impact, for papers by Anthony S. Stein Breakdown of academic impact, for papers by Nicola Gökbuget Breakdown of academic impact, for papers by François Guilhot Breakdown of academic impact, for papers by Morton Coleman Breakdown of academic impact, for papers by Sigurður Y. Kristinsson